A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti‐laminin‐332 IgG with oropharyngeal involvement and the usefulness of <scp>ELISA</scp>

Amber, Kyle T.; Bloom, Romi; Hertl, Michael

doi:10.1111/jdv.13397

Cited by 42 publications

(47 citation statements)

References 32 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…C‐terminal of BP180 appears to play a more significant role in mucous membrane pemphigoid than Nc16a …”

Section: Discussionmentioning

confidence: 99%

“…complement along the basement membrane is diagnostic for pemphigoid and is found in 70% to 90% and 90% to 100% of pemphigoid cases, respectively C-terminal of BP180 appears to play a more significant role in mucous membrane pemphigoid than Nc16a. 19 c Sensitivity highest in patients with IgG activity against α3 domain of laminin 332. 19 the diagnostic skill, location, and timing of biopsies that may reflect…”

Section: Approaches To Maximize Diagnostic Capabilitymentioning

confidence: 99%

“…19 c Sensitivity highest in patients with IgG activity against α3 domain of laminin 332. 19 the diagnostic skill, location, and timing of biopsies that may reflect…”

Section: Approaches To Maximize Diagnostic Capabilitymentioning

confidence: 99%

See 2 more Smart Citations

The spectrum of histopathologic findings in pemphigoid: Avoiding diagnostic pitfalls

et al. 2018

View full text Add to dashboard Cite

While re-epithelialization of subepidermal blisters is a commonly accepted phenomenon, there are no published data demonstrating its incidence. Because only half of the biopsies showed the classic subepidermal blister, it is important to be aware of the spectrum of histopathologic findings that occur in this disease. Specifically, the presence of an intraepidermal blister and/or epidermal necrosis on routine H&E-stained specimens does not preclude the diagnosis of pemphigoid.

show abstract

“…C‐terminal of BP180 appears to play a more significant role in mucous membrane pemphigoid than Nc16a …”

Section: Discussionmentioning

confidence: 99%

Section: Approaches To Maximize Diagnostic Capabilitymentioning

confidence: 99%

See 1 more Smart Citation

The spectrum of histopathologic findings in pemphigoid: Avoiding diagnostic pitfalls

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In order to identify the final target antigen, immunoblotting using the C‐terminal of BP180 and laminin‐332 recombinant proteins is necessary, but facilities in which the procedure can be performed are limited. ELISA (CLEIA) of the NC16a domain of BP180 tests positive in more than half of cases of anti‐BP180 type MMP; however, even in negative cases, the possibility of MMP cannot be ruled out . Recently, an ELISA method using BP180 full‐length recombinant protein has been developed, and it is expected to be clinically applied for the diagnosis of anti‐BP180 type MMP and the evaluation of disease activity …”

Section: Overview Of Pemphigoid Diseasesmentioning

confidence: 99%

“…ELISA (CLEIA) of the NC16a domain of BP180 tests positive in more than half of cases of anti-BP180 type MMP; however, even in negative cases, the possibility of MMP cannot be ruled out. 51,52 Recently, an ELISA method using BP180 full-length recombinant protein has been developed, and it is expected to be clinically applied for the diagnosis of anti-BP180 type MMP and the evaluation of disease activity. 53 Patients are assigned to a low-risk group (localized lesions of oral mucosa and skin) or high-risk group (wide-ranging or advanced oral mucosal lesion, or ocular, genital, nasopharyngeal, laryngeal or esophageal lesion) and the course of treatment is determined.…”

Section: Clinical Manifestations Pathological Findings and Laboratormentioning

confidence: 99%

Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)

Ujiie

Iwata

Yamagami

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

The pemphigoid group is a category of autoimmune subepidermal blistering diseases in which autoantibodies deposit linearly at the epidermal basement membrane zone (BMZ). The main subtypes of pemphigoid mediated by immunoglobulin G autoantibodies are bullous pemphigoid (BP), mucous membrane pemphigoid (MMP) and epidermolysis bullosa acquisita (EBA). To establish the first guidelines approved by the Japanese Dermatological Association for the management of pemphigoid diseases, the Committee for Guidelines for the Management of Pemphigoid Diseases (Including EBA) was founded as part of the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labor and Welfare Research Project on Overcoming Intractable Diseases. These guidelines aim to provide current information for the management of BP, MMP and EBA in Japan. Based on evidence, the guidelines summarize the clinical and immunological manifestations, pathophysiologies, diagnostic criteria, disease severity determination criteria, treatment algorithms and treatment recommendations. Because of the rarity of these diseases, there are few clinical studies with a high degree of evidence, so several parts of these guidelines were established based on the opinions of the Committee. To further optimize these guidelines, periodic revision in line with the new evidence is necessary.

show abstract

Immunobullous Diseases

Schmidt,

Groves

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

The immunobullous disorders represent a group of conditions characterised by antibody‐mediated autoimmune responses against structural elements of the skin resulting in blistering of the skin and/or mucosae. Antibody targets include proteins in the hemidesmosomes basement membrane zone and superficial dermis (pemphigoid group), desmosomes (pemphigus group) and epidermal and tissue‐type transglutaminase (dermatitis herpetiformis). If left untreated, immunobullous disorders are associated with significant morbidity and mortality and thus prompt, accurate diagnosis and treatment are mandatory. Therapeutic options include corticosteroids, steroid‐sparing immunosuppressants such as azathioprine, mycophenolate mofetil and anti‐inflammatory agents such as dapsone and tetracyclines. In severe and/or refractory patients, intravenous immunoglobulin, immunoadsorption and anti‐B‐cell agents such as rituximab may be of benefit. Indeed, recently international and European guidelines have recommended the use of rituximab as first line treatment in moderate and severe pemphigus vulgaris and foliaceous.

show abstract

A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti‐laminin‐332 IgG with oropharyngeal involvement and the usefulness of ELISA

Abstract: Immunodiagnostics play a major role in diagnosing MMP, though limited sensitivity may necessitate several forms of testing for confirmation.

Cited by 42 publications

References 32 publications

The spectrum of histopathologic findings in pemphigoid: Avoiding diagnostic pitfalls

The spectrum of histopathologic findings in pemphigoid: Avoiding diagnostic pitfalls

Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)

Immunobullous Diseases

Contact Info

Product

Resources

About